| DNA-repair defects and olaparib in metastatic prostate cancer J Mateo, S Carreira, S Sandhu, S Miranda, H Mossop, R Perez-Lopez, ... New England Journal of Medicine 373 (18), 1697-1708, 2015 | 2336 | 2015 |
| Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 … T Powles, I Durán, MS Van der Heijden, Y Loriot, NJ Vogelzang, ... The Lancet 391 (10122), 748-757, 2018 | 1408 | 2018 |
| Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer ND James, SA Hussain, E Hall, P Jenkins, J Tremlett, C Rawlings, ... New England Journal of Medicine 366 (16), 1477-1488, 2012 | 1029 | 2012 |
| Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study COVIDSurg Collaborative Anaesthesia 76 (6), 748-758, 2021 | 566* | 2021 |
| Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ... The Lancet Oncology 22 (7), 931-945, 2021 | 478 | 2021 |
| Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma … T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ... The Lancet Oncology 21 (12), 1574-1588, 2020 | 425 | 2020 |
| The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers PJ Johnson, SJ Pirrie, TF Cox, S Berhane, M Teng, D Palmer, J Morse, ... Cancer Epidemiology, Biomarkers & Prevention 23 (1), 144-153, 2014 | 304 | 2014 |
| Chemotherapy for breast cancer MSU Hassan, J Ansari, D Spooner, SA Hussain Oncology reports 24 (5), 1121-1131, 2010 | 263 | 2010 |
| Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer SA Hussain, R Ganesan, G Reynolds, L Gross, A Stevens, J Pastorek, ... British journal of cancer 96 (1), 104-109, 2007 | 255 | 2007 |
| Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised … DP Petrylak, R De Wit, KN Chi, A Drakaki, CN Sternberg, H Nishiyama, ... The Lancet 390 (10109), 2266-2277, 2017 | 251 | 2017 |
| Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1 M Smith, J De Bono, C Sternberg, S Le Moulec, S Oudard, U De Giorgi, ... Journal of Clinical Oncology 34 (25), 3005-3013, 2016 | 247 | 2016 |
| Effect of robot-assisted radical cystectomy with intracorporeal urinary diversion vs open radical cystectomy on 90-day morbidity and mortality among patients with bladder … JWF Catto, P Khetrapal, F Ricciardi, G Ambler, NR Williams, ... Jama 327 (21), 2092-2103, 2022 | 202 | 2022 |
| Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor … T Powles, RA Huddart, T Elliott, SJ Sarker, C Ackerman, R Jones, ... Journal of Clinical Oncology 35 (1), 48-55, 2017 | 199 | 2017 |
| Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle‐invasive bladder cancer MD Galsky, SK Pal, S Chowdhury, LC Harshman, SJ Crabb, YN Wong, ... Cancer 121 (15), 2586-2593, 2015 | 193 | 2015 |
| Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954 G Chung-Faye, D Palmer, D Anderson, J Clark, M Downes, J Baddeley, ... Clinical cancer research 7 (9), 2662-2668, 2001 | 193 | 2001 |
| Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin PJ Mulholland, DR Ferry, D Anderson, SA Hussain, AM Young, JE Cook, ... Annals of Oncology 12 (2), 245-248, 2001 | 189 | 2001 |
| The systemic treatment of advanced and metastatic bladder cancer SA Hussain, ND James The Lancet Oncology 4 (8), 489-497, 2003 | 149 | 2003 |
| Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004) RA Huddart, E Hall, SA Hussain, P Jenkins, C Rawlings, J Tremlett, ... International Journal of Radiation Oncology* Biology* Physics 87 (2), 261-269, 2013 | 146 | 2013 |
| Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials A Choudhury, N Porta, E Hall, YP Song, R Owen, R MacKay, CML West, ... The lancet oncology 22 (2), 246-255, 2021 | 126 | 2021 |
| A randomised phase 2 study of AZD2014 versus everolimus in patients with VEGF-refractory metastatic clear cell renal cancer T Powles, M Wheater, O Din, T Geldart, E Boleti, A Stockdale, S Sundar, ... European urology 69 (3), 450-456, 2016 | 107 | 2016 |
Robert HuddartInstitution of Cancer ResearchVerified email at icr.ac.uk
